Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial

NCT07059377 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.

NCT NCT07059377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07059377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial
Lead sponsor
Ottawa Heart Institute Research Corporation
Phase
Phase 3
Overall status
Recruiting
Start date
February 13, 2026
Completion date
July 31, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, nicotine addiction, tobacco dependence